Tuesday, August 25, 2026
60 articles analyzed
Updated Aug 25, 10:38 AM · 60 sources analyzed
Key Takeaways
Pharvaris terminated its Phase 2 oral HAE prophylaxis study with no data disclosed, a meaningful pipeline setback for the company.
AbbVie's emraclidine schizophrenia extension study was terminated, raising fresh questions about the $8.7B Cerevel acquisition's CNS thesis.
A bioRxiv preprint describes a selective CD28 small molecule inhibitor for IBD that avoids CTLA-4 suppression — a potentially differentiated mechanism worth tracking.
🏆 Winner
Camurus AB — Phase 3 of CAM2029 in acromegaly marked complete, advancing the lead asset toward a potential regulatory filing.
📉 Loser
AbbVie — termination of emraclidine's long-term extension study adds pressure to the centerpiece CNS asset of its multi-billion dollar Cereval acquisition.
🔭 Watch Next
Viridian Therapeutics Phase 3 veligrotug topline data in thyroid eye disease, expected to follow registry completion and serving as the defining readout for whether the company can compete with Tepezza.
CD28 inhibitor shows IBD signal without blocking CTLA-4
Researchers published a bioRxiv preprint describing a small molecule that selectively blocks CD28 costimulation — a key signal that activates pathogenic T cells in inflammatory bowel disease — without simultaneously suppressing CTLA-4, a safety checkpoint that current biologic approaches inevitably hit. The selectivity advantage is the core thesis: existing B7-directed biologics like abatacept blunt both CD28 and CTLA-4 signaling, limiting their tolerability profile in autoimmune indications. If the selectivity holds in human studies, this class could offer a cleaner mechanistic entry point into IBD and potentially other T cell-driven diseases where CTLA-4 co-inhibition is undesirable.
bioRxiv ↗Selective CD28 small molecule inhibitor restrains IBD T-cell pathology without suppressing CTLA-4
Using a NanoBiT split-luciferase screening platform, researchers identified a small molecule that selectively blocks CD28 costimulation and reduces pathogenic T-cell responses in inflammatory bowel disease models without co-inhibiting CTLA-4 signaling.
Why it matters
The IBD drug development landscape is dominated by biologics targeting TNF, IL-12/23, and integrins; a selective oral CD28 inhibitor would represent a mechanistically distinct entry point that could attract significant BD interest if preclinical selectivity holds in human tissue models. The key investor question is whether selectivity for CD28 over CTLA-4 is durable at therapeutically relevant concentrations.
What to watch
Watch for peer-reviewed publication and any IND-enabling study announcements from the originating group or a licensing partner, which would signal commercial translation intent.
Pharvaris
PHA-022121 in Hereditary Angioedema Type I and Type II
The dose-ranging prophylaxis study of oral PHA-022121 was terminated. No efficacy or safety data have been released from this registry update; the termination rationale has not been publicly disclosed in this source.
Why it matters
Program termination at the dose-ranging stage is a meaningful setback for Pharvaris's oral HAE franchise — it suggests either the dose range failed to demonstrate an acceptable efficacy or tolerability profile, or strategic priorities shifted. Investors will need clarity on which before reassessing the pipeline thesis.
What to watch
Watch for a formal company statement or investor communication explaining the termination rationale, and whether Pharvaris pursues an amended protocol or exits the prophylaxis segment entirely.
AbbVie
Emraclidine (CVL-231) in Schizophrenia
The long-term safety and tolerability extension study of oral emraclidine in schizophrenia (NCT05443724) has been marked Terminated on ClinicalTrials.gov. No safety or efficacy outcome data are disclosed in this registry update.
Why it matters
AbbVie paid approximately $8.7 billion for Cerevel partly on the promise of emraclidine's differentiated mechanism in schizophrenia; a terminated extension study, even without disclosed reasons, will raise questions about whether the program is advancing to Phase 3 on the original timeline.
What to watch
Watch for AbbVie's next pipeline update or investor day commentary on emraclidine's Phase 3 readiness and whether a pivotal trial initiation remains on track.
Hyperpolarized Xenon-129 MRI evaluated as functional lung imaging biomarker in IPF
A Phase 2 study at Duke University assessed whether inhaled hyperpolarized 129Xe MRI can detect and visualize impaired lung function in idiopathic pulmonary fibrosis beyond what standard spirometry captures.
Why it matters
IPF drug developers including Boehringer Ingelheim, Roche, and a wave of smaller biotechs pursuing novel antifibrotic mechanisms face the persistent challenge of insensitive and slow-moving endpoints; if Xe-129 MRI data from this study prove compelling, it could shift trial design paradigms and reduce development timelines for the next generation of IPF assets.
What to watch
Watch for publication of the Duke Xe-129 MRI study results and whether the FDA's pulmonary division engages with the imaging modality as an acceptable surrogate or enrichment biomarker in future IPF trial guidance.
The dose-ranging prophylaxis study of oral PHA-022121 was terminated. No efficacy or safety data have been released from this registry update; the termination rationale has not been publicly disclosed in this source.
Why it matters
A terminated Phase 2 dose-ranging study in HAE removes a potential oral prophylaxis competitor from the field, modestly benefiting KALVISTA and other oral plasma kallikrein inhibitor developers.
Analysis
Program termination at the dose-ranging stage is a meaningful setback for Pharvaris's oral HAE franchise — it suggests either the dose range failed to demonstrate an acceptable efficacy or tolerability profile, or strategic priorities shifted. Investors will need clarity on which before reassessing the pipeline thesis.
What to watch
Watch for a formal company statement or investor communication explaining the termination rationale, and whether Pharvaris pursues an amended protocol or exits the prophylaxis segment entirely.
The Phase 3 safety, tolerability, and efficacy study of veligrotug in thyroid eye disease (NCT05176639) has been marked Completed on ClinicalTrials.gov. No efficacy or safety outcome data have been released via this registry update.
Why it matters
Study completion sets the stage for a data readout that will determine whether veligrotug can compete with Amgen's teprotumumab (Tepezza) in the IGF-1R inhibitor class for TED.
Analysis
Registry completion alone carries no signal, but it moves the clock forward on a data readout that will define Viridian's competitive position in the TED market — a space where Tepezza holds strong first-mover advantage and the bar for differentiation is high.
What to watch
Watch for Viridian's topline Phase 3 efficacy data announcement, expected to follow study completion and likely to be presented at a major ophthalmology or endocrinology conference.
The long-term safety and tolerability extension study of oral emraclidine in schizophrenia (NCT05443724) has been marked Terminated on ClinicalTrials.gov. No safety or efficacy outcome data are disclosed in this registry update.
Why it matters
Termination of an extension study for emraclidine — a selective M4 muscarinic agonist AbbVie acquired via its Cerevel purchase — adds pressure to AbbVie's CNS pipeline at a time when the mechanistic class is under scrutiny following mixed results industry-wide.
Analysis
AbbVie paid approximately $8.7 billion for Cerevel partly on the promise of emraclidine's differentiated mechanism in schizophrenia; a terminated extension study, even without disclosed reasons, will raise questions about whether the program is advancing to Phase 3 on the original timeline.
What to watch
Watch for AbbVie's next pipeline update or investor day commentary on emraclidine's Phase 3 readiness and whether a pivotal trial initiation remains on track.
The Phase 2b randomized, double-blind, placebo-controlled study of oral EDP-938 in non-hospitalized high-risk adults with confirmed RSV (NCT05568706) has been marked Completed on ClinicalTrials.gov. No efficacy or safety outcome data are provided in this registry update.
Why it matters
Completion of this Phase 2b study positions Enanta for a potential data readout in the RSV antiviral space, where Pfizer's Paxlovid-style urgency around respiratory antivirals has reinvigorated commercial interest.
Analysis
Enanta's RSV program has been a critical pipeline pillar following setbacks elsewhere; the Phase 2b completion means results could define whether EDP-938 has a viable path forward or whether the company faces further portfolio pressure.
What to watch
Watch for Enanta's topline EDP-938 Phase 2b data announcement, which should follow registry completion and will be closely watched given the competitive RSV antiviral landscape.
The Phase 3 placebo-controlled study of CAM2029 once-monthly subcutaneous depot in acromegaly (NCT04076462) has been marked Completed on ClinicalTrials.gov. No efficacy or safety data are disclosed in this registry update.
Why it matters
Completion advances CAM2029 toward a potential regulatory filing in acromegaly, where Camurus is targeting a more convenient subcutaneous formulation compared to existing long-acting somatostatin analogues.
Analysis
CAM2029 is Camurus's lead late-stage asset; Phase 3 completion moves the program toward a regulatory submission decision, but the investment thesis depends on the data demonstrating meaningful differentiation from established formulations in a niche but stable endocrinology market.
What to watch
Watch for Camurus's Phase 3 data disclosure and any regulatory filing announcement in acromegaly, likely in the next one to two quarters following study completion.
Selective CD28 small molecule inhibitor restrains IBD T-cell pathology without suppressing CTLA-4
Using a NanoBiT split-luciferase screening platform, researchers identified a small molecule that selectively blocks CD28 costimulation and reduces pathogenic T-cell responses in inflammatory bowel disease models without co-inhibiting CTLA-4 signaling.
Why it matters
If the selectivity profile translates clinically, this compound class could offer a safer oral or small-molecule alternative to biologic B7-directed agents like abatacept, which unavoidably suppress CTLA-4 and carry immunosuppression liabilities.
Analysis
The IBD drug development landscape is dominated by biologics targeting TNF, IL-12/23, and integrins; a selective oral CD28 inhibitor would represent a mechanistically distinct entry point that could attract significant BD interest if preclinical selectivity holds in human tissue models. The key investor question is whether selectivity for CD28 over CTLA-4 is durable at therapeutically relevant concentrations.
What to watch
Watch for peer-reviewed publication and any IND-enabling study announcements from the originating group or a licensing partner, which would signal commercial translation intent.
Oral DXM-bupropion combination studied for opioid use disorder safety interactions
A Phase Ib/2a drug-drug interaction study at Virginia Commonwealth University evaluated the safety of 45mg dextromethorphan combined with 105mg bupropion alongside the opioid buprenorphine in subjects with opioid or substance use disorders.
Why it matters
Characterizing the interaction profile between the DXM/bupropion combination (the mechanism behind Axsome's AXS-05 and related assets) and opioid agonists is a prerequisite for expanding this drug class into addiction indications where co-administration is common.
Analysis
This study's completion may generate safety data relevant to Axsome Therapeutics and any developer pursuing DXM-bupropion combinations in CNS indications beyond depression; a clean interaction profile would support label expansion and reduce prescriber hesitancy in polysubstance populations.
What to watch
Watch for data publication from NCT05976646 and any follow-on IND filings targeting opioid use disorder with DXM-based combinations.
Hyperpolarized Xenon-129 MRI evaluated as functional lung imaging biomarker in IPF
A Phase 2 study at Duke University assessed whether inhaled hyperpolarized 129Xe MRI can detect and visualize impaired lung function in idiopathic pulmonary fibrosis beyond what standard spirometry captures.
Why it matters
A validated functional imaging biomarker for IPF could accelerate drug development by enabling smaller, shorter trials with sensitive intermediate endpoints rather than relying on FVC decline over 52 weeks as the standard primary measure.
Analysis
IPF drug developers including Boehringer Ingelheim, Roche, and a wave of smaller biotechs pursuing novel antifibrotic mechanisms face the persistent challenge of insensitive and slow-moving endpoints; if Xe-129 MRI data from this study prove compelling, it could shift trial design paradigms and reduce development timelines for the next generation of IPF assets.
What to watch
Watch for publication of the Duke Xe-129 MRI study results and whether the FDA's pulmonary division engages with the imaging modality as an acceptable surrogate or enrichment biomarker in future IPF trial guidance.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Erasca filed an 8-K with the SEC under Item 8.01 on August 24, 2026. The specific disclosure has not been detailed in the source summary, and the filing type (Item 8.01 covers other events not elsewhere specified) does not indicate a routine administrative action — further review of the full filing is warranted to determine materiality.
SEC EDGAR ↗Every weekday morning
Start your morning with the stories moving biotech.
Clinical readouts · FDA watch · Deal flow · Pipeline pulse